• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Research on Classifying Celestial Objects, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

    3/11/25 10:49:56 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $REGN alert in real time by email

    $250,000 top award goes to Matteo Paz in America's longest running and most distinguished science and math competition

    TARRYTOWN, N.Y. and WASHINGTON, March 11, 2025 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Matteo Paz, 18, of Pasadena, California, won the top award of $250,000 in the 2025 Regeneron Science Talent Search, the U.S.'s oldest and most prestigious science and math competition for high school seniors.

    Congratulations to the top three Regeneron Science Talent Search award winners, Ava Grace Cummings, Matteo Paz and Owen Jianwen Zhang (left to right) Photo Credit: Chris Ayers Photography/Licensed by Society for Science

    Now in its 84th year, the competition celebrates and rewards young innovators who are applying their Science, Technology, Engineering and Math (STEM) talent and leadership skills to push the boundaries of discovery and address today's pressing challenges.

    Forty finalists, including Matteo, were honored this evening during an award ceremony at the National Building Museum in Washington, D.C, where they were awarded more than $1.8 million in prizes for their groundbreaking research, exceptional problem-solving skills and potential to shape the future of STEM.

    • Matteo Paz, 18, of Pasadena, California, won first place and $250,000 for designing machine-learning algorithms to efficiently comb through 200 billion entries of raw NEOWISE infrared full-sky data. By analyzing tiny changes in infrared radiation, the AI sorted the objects into 10 classes. He found 1.5 million new potential objects.



    • Second place and $175,000 went to Ava Grace Cummings, 18, of Smithfield, North Carolina, for creating a fruit fly model of STAC3 disorder, or Native American myopathy (a rare genetic muscle disease). She found that the common nettle herb, alone or combined with the experimental drug Tirasemtiv, improved movement in both adult flies and larvae.



    • Third place and $150,000 went to Owen Jianwen Zhang, 18, of Bellevue, Washington, who solved a long-standing math problem about objects called 3-uniform hypergraphs. He proved a maximum value for how many 3-uniform hypergraphs can have similar structures but differing connections. Owen's results have applications in computer science.

    "Congratulations to the winners of this year's Regeneron Science Talent Search," said Maya Ajmera, President and CEO, Society for Science and Executive Publisher, Science News. "The remarkable creativity and dedication of these students bring renewed hope for our future. Driven by their ingenuity, these young scientists are developing groundbreaking solutions that have the potential to transform our world and propel society forward." 

    The Regeneron Science Talent Search provides a national platform for high school seniors to showcase original, innovative STEM research that proposes novel solutions to real-world issues. Finalists are evaluated for their scientific rigor, originality, critical thinking, leadership potential and commitment to drive meaningful impact across crucial STEM fields.

    "The Science Talent Search changed my life. At my high school, STS winners were treated like star athletes, and I never imagined I would belong in such an amazing group of kids who were operating at a whole different level than I had ever seen," said George D. Yancopoulos, co-Founder, Board co-Chair, President and Chief Scientific Officer of Regeneron and a 1976 Science Talent Search finalist and top winner. "The experience of competing in STS and being named a top winner gave me the confidence to devote my life to science. So, congratulations to this year's finalists and winners, you are America's best and brightest. I hope this moment inspires you to push boundaries, challenge assumptions and use your brilliance to change the world."

    Other top honors from the competition include:

    • Fourth Place: Logan Lee, 18, of Honolulu, Hawaii received a $100,000 award for helping sterile male mosquitoes survive in the wild. These males are important in mosquito control. Logan improved their survival by giving them a transplant of wild mosquito bacteria. His transplant helped the sterile mosquitoes grow faster and survive better in the wild.



    • Fifth Place: Rivka Lipkovitz, 18, of San Francisco, California received a $90,000 award for using statistical modeling to study U.S. voter ID laws. She found that presidential election turnout dropped by 2.4% in states that passed strict laws after 2008. Turnout for midterm elections increased. Knowing how laws affect turnout can help shape future policies.



    • Sixth Place: Melody Heeju Hong, 17, of Wantagh, New York received a $80,000 award for developing a powerful, flexible statistical model for mapping sites called trans-methylation quantitative trait loci (trans-mQTL) within the human genome. These sites are key to understanding the interplay between genes and environment in disease and aging.



    • Seventh Place: Kevin Shen, 18, of Olympia, Washington received a $70,000 award for building a custom flight computer to control a 3D-printed airplane with oblique wings. These aircraft can be more fuel-efficient but are hard to control. His oblique-wing aircraft and flight computer improved flight efficiency by 9.2%.



    • Eighth Place: Minghao Zou, 18, of Santa Clara, California received a $60,000 award for simulating protons to probe environments that produce subatomic particles called neutrinos. He created an algorithm mimicking extreme astrophysical conditions, such as electromagnetic and gravitational forces and interactions with nearby particles. He verified it using known cases of particle motion.



    • Ninth Place: Thanush Patlolla, 17, of Cary, North Carolina received a $50,000 award for approximating the density of electrons using a finite nuclear model. Using a mathematical strategy called a density function, he created a model to map electrons in a nuclear simulation. The map increased the accuracy of energy distribution predictions by 0.6%.



    • Tenth Place: Ray Zhang, 17, of Chantilly, Virginia received a $40,000 award for studying how to better treat drug-resistant Fusarium fungal infections. Ray studied how the fungus builds sticky communities of cells that resist drug treatment. He also found that using a combination of drugs better controlled the fungus.



    • Akilan Sankaran, 17, of Albuquerque, New Mexico was named the Seaborg Award winner and selected to speak on behalf of the Regeneron Science Talent Search Class of 2025. The 40 finalists chose Akilan as the student who best exemplifies their class and the legacy of nuclear chemist Glenn T. Seaborg, who won the Nobel Prize for Chemistry in 1951 and served on the Society's Board of Trustees for 30 years.

    All other finalists received $25,000. All 40 finalists join a distinguished group of Science Talent Search alumni, many of whom have gone on to achieve world-changing careers in STEM, with some earning esteemed honors, including the Nobel Prize, National Medal of Science, and MacArthur Fellowship. In total, Regeneron awarded $3.1 million in prizes, including $2,000 to each top scholar and their school.

    Learn more about Regeneron Science Talent Search at https://www.societyforscience.org/regeneron-sts/ and learn about all their research projects at our Virtual Public Showcase.

    For media resources, visit  https://www.societyforscience.org/2025-regeneron-science-talent-search-media-kit

    About Society for Science 

    Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its outreach and equity programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at www.societyforscience.org and follow us on Facebook, Twitter, Instagram and Snapchat (Society4Science).

    About Regeneron 

    Regeneron (NASDAQ:REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases and rare diseases.

    Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious disease, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most "community-minded" companies in the U.S. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro-bono and matching gift programs. Our most significant philanthropic commitments are in the area of science education, including the Regeneron Science Talent Search and the Regeneron International Science and Engineering Fair (ISEF).

    For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

    Media Contacts

    Joseph Brown, Regeneron

    386-283-1323, [email protected]  

    Gayle Kansagor, Society for Science

    703-489-1131, [email protected] 

    (PRNewsfoto/Society for Science)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/regeneron-science-talent-search-2025-awards-more-than-1-8-million-to-high-school-seniors-for-innovative-research-on-classifying-celestial-objects-treating-a-rare-muscle-disease-and-solving-a-long-standing-math-problem-302399274.html

    SOURCE Society for Science

    Get the next $REGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $REGN

    DatePrice TargetRatingAnalyst
    3/31/2026$875.00Overweight
    Piper Sandler
    3/6/2026$923.00Overweight
    Barclays
    1/7/2026$860.00Underperform → Buy
    BofA Securities
    12/3/2025$767.00Overweight → Equal-Weight
    Morgan Stanley
    11/24/2025$798.00Buy
    Truist
    11/24/2025$255.00Buy
    HSBC Securities
    11/13/2025$650.00Sector Perform
    Scotiabank
    8/14/2025$890.00Buy
    Rothschild & Co Redburn
    More analyst ratings

    $REGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on Regeneron Pharma with a new price target

    Piper Sandler resumed coverage of Regeneron Pharma with a rating of Overweight and set a new price target of $875.00

    3/31/26 8:17:54 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Regeneron Pharma with a new price target

    Barclays initiated coverage of Regeneron Pharma with a rating of Overweight and set a new price target of $923.00

    3/6/26 8:35:41 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Pharma upgraded by BofA Securities with a new price target

    BofA Securities upgraded Regeneron Pharma from Underperform to Buy and set a new price target of $860.00

    1/7/26 8:45:07 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Regeneron Pharmaceuticals Inc.

    SCHEDULE 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    3/27/26 11:37:27 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 13F-HR filed by Regeneron Pharmaceuticals Inc.

    13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    2/6/26 5:06:37 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Regeneron Pharmaceuticals Inc.

    10-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)

    2/4/26 9:08:38 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 20, 2022 - FDA Approves First Treatment for Eosinophilic Esophagitis, a Chronic Immune Disorder

    For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis

    5/20/22 3:11:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

    Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record dataCollaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continue to drive drug discovery and development and empower AI training algorithms to deliver digital health solutions of the future for consumers, patients and providersTARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 2, 2026 /CNW/ -- TriNetX® and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced a strategic collaboration to support Regeneron's capabilities in drug discovery and development, as well a

    4/2/26 4:30:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

    Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database Growing database will continue to drive drug discovery and development and empower AI training algorithms to deliver digital health solutions of the future for consumers, patients and providers TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and TriNetX® today announced a strategic collaboration to support Regeneron's capabilities in drug discovery and de

    4/2/26 4:30:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)

    Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing regimen allows patients with wAMD and DME to be treated as infrequently as 2 to 3 times a year, further extending the widest range of dosing intervals of any approved injectable anti-VEGF TARRYTOWN, N.Y., April 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of dosing intervals for EYLEA HD® (aflibercept) up to every 20 weeks for patients with wet age-related macular degeneratio

    4/2/26 12:00:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ryan Arthur F

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    4/3/26 4:01:09 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Arthur F sold $78,550 worth of shares (100 units at $785.50), decreasing direct ownership by 0.56% to 17,703 units (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    3/3/26 4:01:53 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Zoghbi Huda Y exercised 1,638 shares at a strike of $376.69 and sold $1,279,812 worth of shares (1,638 units at $781.33) (SEC Form 4)

    4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)

    2/23/26 4:55:58 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Financials

    Live finance-specific insights

    View All

    Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026

    TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2026 financial and operating results on Wednesday, April 29, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detail

    3/25/26 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

    TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2025 financial and operating results on Friday, January 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation

    1/2/26 4:05:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

    All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over time Across all dose groups, 95% (19 of 20 patients) of all evaluable VGPR+ patients achieved minimal residual disease negative status Data featured in an ASH oral presentation; LINKER-MM4 is the first clinical trial to evaluate a BCMAxCD3 bispecific monotherapy in NDMM and is part of a broad clinical development program evaluating Lynozyfic-based regimens in earlier lines of treatment Regeneron to host virtual ‘Regeneron Roundtable' investor event to dis

    12/7/25 4:30:00 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Leadership Updates

    Live Leadership Updates

    View All

    Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

    TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days' Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the 2025 calendar year, enabling more patients to affordably access essential medicines that help protect their vision. "We are proud to support Good Days with this unprecedented philanthropic effort," said Leonard Schleifer, M.D., Ph.D.,

    6/24/25 7:30:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs

    TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie

    1/30/24 7:00:41 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

    NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

    10/18/23 9:00:00 AM ET
    $AZN
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $REGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/13/24 5:12:22 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 6:19:03 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Regeneron Pharmaceuticals Inc. (Amendment)

    SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)

    2/9/24 9:49:31 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care